Price
No data yet.
Social Signal Score
Revenue
$32.36M+1104.73%Company Profile
- CEO
- Nasrat Hakim
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 65
- Beta
- 0.40
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 6.32
Financials
Revenue
$32.36M+1104.7%Net Income
$5.91M+39.5%EBITDA
$8.02M+79.8%Free Cash Flow
$9.26MEPS (diluted)
$0.01-82.7%Shares Outstanding (diluted)
1.13B+38.3%Operating Expenses
$5.58MCash & Debt
$38.94MRevenue by Segment (annual)
$148.87MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $148.87M | $44.87M | $0.04 |
| 2025 | $84.04M | $-4.31M | $-0.00 |
| 2024 | $56.63M | $20.11M | $0.02 |
| 2023 | $34.16M | $4.41M | $4.35 |
| 2022 | $32.26M | $8.90M | $0.01 |
| 2021 | $25.38M | $5.09M | $0.01 |
| 2020 | $17.99M | $-2.24M | $-0.00 |
| 2019 | $7.57M | $-9.28M | $-0.01 |
| 2018 | $7.46M | $-3.67M | $-0.00 |
| 2017 | $9.64M | $3.81M | $0.03 |
| 2016 | $12.50M | $-683.0K | $-0.00 |
| 2015 | $5.02M | $28.93M | $0.05 |
| 2014 | $4.60M | $-96.58M | $-0.21 |
| 2013 | $3.40M | $1.49M | $0.00 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ELTP's reported EPS growth of 19.1% a year over 13 years.
- EPS in 5 years
- $0.10
- Implied price
- $0.90
- Return from $0.22
- 32.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.45 — today's price is already 50.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| 9.1% | 7.6% | 15.1% | 21.0% | 26.0% | 30.3% |
| 14.1% | 12.5% | 20.4% | 26.6% | 31.8% | 36.2% |
| 19.1% | 17.5% | 25.6% | 32.1% | 37.5% | 42.2% |
| 24.1% | 22.4% | 30.9% | 37.7% | 43.3% | 48.2% |
| 29.1% | 27.3% | 36.2% | 43.2% | 49.1% | 54.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
23-53.33%Social Signal Score
Mentions (7)
- Newszacks.com·25d ago·Negative
ELTP Downgraded to Neutral on Pricing Pressure & Limited Visibility Elite Pharmaceuticals' downgrade to Neutral cites pricing pressure, weaker revenue and margins, and limited visibility into new-product contributions.
View source ↗ - Newszacks.com·41d ago·Positive
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy? Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
View source ↗ - Newszacks.com·47d ago·Negative
Elite Pharmaceuticals Stock Plunges Post Q1 Earnings, Revenues Fall Y/Y ELTP's first-quarter fiscal 2027 revenues decline as generic competition and lower pricing offset higher volumes, while pipeline development remains a growth focus.
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call Transcript Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·52d ago·Neutral
Elite Pharmaceuticals Q1 Earnings Call Highlights Elite Pharmaceuticals OTCMKTS: ELTP reported first-quarter fiscal 2027 revenue of $32.4 million and operating profit of $7.5 million, with Chief Financial Officer Carter Ward describing both measures as steady and consistent with the preceding three quarters.
View source ↗ - Newsnewsfilecorp.com·53d ago·Negative
…Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2027 ended June 30, 2026 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2026, were $32.4 million, a decrease of $7.9 million or approximat…
View source ↗ - Newsnewsfilecorp.com·56d ago·Neutral
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026 Financials for First Quarter of Fiscal Year 2027 Ended June 30, 2026 will be released on Thursday, August 13, 2026 Northvale, New Jersey--(Newsfile Corp. - August 10, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that t
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Estimates and results for ELTP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELTP officers and directors.
- Bought
- $18k
- Sold
- $2.1m
2 trades
21 trades
- Dash Barry Hbought
- Plassche Douglassold
- Elite Pharmaceuticals Inc /nv/sold
- Kirkov Kirkobought
- Plassche Douglassold
- Plassche Douglassold
- Plassche Douglassold
- Treppel Jerrysold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ELTP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.